

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> <b>A61K 9/16, B01J 10/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 90/13285</b> <b>(43) International Publication Date:</b> 15 November 1990 (15.11.90)
<b>(21) International Application Number:</b> PCT/US90/02421 <b>(22) International Filing Date:</b> 1 May 1990 (01.05.90) <b>(30) Priority data:</b> 345,684 1 May 1989 (01.05.89) US <b>(71) Applicant:</b> ENZYTECH, INC. [US/US]; 763D Concord Avenue, Cambridge, MA 02138 (US). <b>(72) Inventors:</b> GOMBOTZ, Wayne, R. ; 492 Marrett Road, Lexington, MA 02173 (US). HEALY, Michael, S. ; 185 Walnut Street, East Bridgewater, MA 02333 (US). BROWN, Larry, R. ; 38 Cummings Road, Newton, MA 02159-1753 (US). AUER, Henry, E. ; 805 Mt. Auburn Street, #53, Watertown, MA 02172 (US).		<b>(74) Agents:</b> PABST, Patrea, L. et al.; Kilpatrick & Cody, 100 Peachtree Street, Suite 3100, Atlanta, GA 30303 (US). <b>(81) Designated States:</b> AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent). <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> PROCESS FOR PRODUCING SMALL PARTICLES OF BIOLOGICALLY ACTIVE MOLECULES  <b>(57) Abstract</b>  Small diameter particles of biologically active molecules are produced by atomizing solutions of the molecules through a nozzle into very cold liquified gases, which immediately freeze the atomized droplets. The resulting frozen particles having diameters of approximately 10 to 90 micrometers are lyophilized to produce porous particles, suspended in a non-solvent for the molecules, and exposed to ultrasonic energy or homogenization to produce particles having diameters of 0.1 to 10 micrometers with greater than 70 to 95 % of the initial biological activity of the molecules in solution.		

### DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

#### FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Fasso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
DE	Germany, Federal Republic of	LU	Luxembourg	TC	Togo
DK	Denmark			US	United States of America

- 1 -  
**PROCESS FOR PRODUCING SMALL PARTICLES  
OF BIOLOGICALLY ACTIVE MOLECULES**

**BACKGROUND OF THE INVENTION**

This invention relates to processes for producing particles  
5 of biological molecules at low temperatures using ultrasonic energy.

It is frequently desirable to incorporate biologically active  
proteins or other molecules within a polymeric matrix for use in  
controlled drug delivery or other applications requiring stable, uniform  
dispersions of material. Reduction of the particle size of such  
10 substances, particularly those that have biological activity such as  
proteins, is an important part in the design of pharmaceutical  
formulations.

For example, in the preparation of injectable polymeric  
microspheres for controlled drug delivery systems, the microspheres  
15 should be 50 micrometers or less in diameter. In order to achieve a  
homogeneous distribution of drug particles throughout the matrix of  
the microsphere, the particles should have diameters much smaller  
than that of the microsphere itself. Smaller diameter particles loaded  
in such a system will result in more desirable release kinetics and can  
20 help eliminate the initial large amount of drug that is often released  
(the "burst effect") from these systems. By controlling the particle size  
of biological molecules in a controlled release device, one can also  
vary the release rate of drug from these systems, as described by  
Brown, et al., in "Controlled Release of Insulin from Polymer  
25 Matrices", *Diabetes*, 35, 684-691 (1986).

Most small particles of compounds to be used for  
pharmaceutical applications are prepared using conventional  
techniques such as spray drying, milling, grinding and lyophilization and  
sieving. Each of these techniques can reduce the particle size of the  
30 materials of interest, but the diameters are often not small enough for  
controlled release microsphere systems. These methods also have  
other disadvantages. Spray drying can reduce particles to sizes of five  
micrometers or less, but biologically active proteins can become

-2-

inactivated in the process due to denaturation at the aqueous air interface and by exposure to heat generated to evaporate the solvent. Spray drying is also inefficient and much material is lost due to sticking to the large surface area of the apparatus.

5           Milling and grinding can produce particles having diameters of only five micrometers, however, many of the particles are much larger in size. Because milling and grinding both require large amounts of material, these techniques are not very amenable to expensive biologically active proteins which can often be obtained only  
10 in small amounts. Milling and grinding can also result in denaturation of proteins. Sieving of lyophilized powders results in particle sizes of about 70 micrometers or greater.

It is therefore an object of the present invention to provide a method for producing small particles of biological molecules.

15           It is a further object of the present invention to provide particles of biologically active molecules that can be uniformly dispersed in a polymeric matrix for controlled release of the biologically active substance.

### SUMMARY OF THE INVENTION

20           A method for producing small particles of biologically active molecules ranging in diameter from approximately 0.1 to ten micrometers which retain greater than 70% to 95% of their original biological activity, wherein the yield of particles of the biologically active molecules is 80% or greater. The technique can be used to  
25 reduce the particle size in preparations of biologically active molecules, including macromolecules such as proteins or smaller molecules such as steroids, amino acids, or synthetic drugs, while maintaining the activity of the molecules. The process can also be used to reduce the particle size of other molecules that are not

biologically active, such as sugars or mixtures of these molecules with proteins.

The process for reducing the particle size of these compounds involves two principal steps. In the first step the molecules of interest are dissolved in a solvent and atomized into a low temperature liquified gas. The liquid gas is then evaporated, leaving frozen spherical particles containing solvent and the material of interest. The solvent is removed from the frozen spheres by lyophilization, resulting in the formation of porous spheres having diameters in the range of 10 to 60 micrometers. These spheres can be used as is, if larger particles are desired, or, if smaller particles are desired, they can be suspended in a non-solvent and exposed to ultrasonic energy or other mechanical forces to break the spheres into smaller particles having diameters in the range of from about 0.1 to 10 micrometers. The porous spherical particles or the smaller particles can be suspended in polymer or pharmaceutical carrier-solvent solutions and entrapped for use in drug delivery systems since the particles can be homogeneously dispersed throughout the matrix, resulting in reproducible and controllable release kinetics.

## **BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1 is a schematic of the formation of porous spheres of biological molecules according to the method of the present invention.

Figure 2 is a schematic of the formation of small particles of biological molecules from the porous spheres of Figure 1 according to the method of the present invention.

Figure 3 is a graph of horse radish peroxidase particle size (micrometers) versus ultrasonication time (seconds), using the process of the present invention.

Figure 4 is a graph of the mean size (micrometers) for particles of dextran versus the concentration of dextran in solution (% w/v), when the particles are made using the processes of the present invention.

5           Figure 5 shows the spectra of the second derivative of absorption with respect to wavelength of fresh hemoglobin, hemoglobin treated with the particle size reduction process of the present invention and hemoglobin denatured in 6 M guanidinium chloride.

## 10                   DETAILED DESCRIPTION OF THE INVENTION

Many of the prior art methods for forming small particles of biological molecules either yield large diameter particles, result in loss of some of the material, or cause a significant loss of biological activity. In contrast, the process of the present invention results in the  
15   size reduction of particles of biological molecules while maintaining greater than 70% of their original biological activity, and usually greater than 90-95% of the starting biological activity, as well as retaining 80% or more of the starting material.

Substances which can be used in this process include  
20   proteins, carbohydrates such as natural or synthetic polysaccharides and sugars, nucleotides, and other biologically active inorganic and organic molecules having a wide range of molecular weights. Representative examples of biologically useful polypeptides include, among others, nucleoproteins, glycoproteins, and lipoproteins. Many  
25   protein classes are suitable for use in this process, including antibodies, enzymes, hormonally active polypeptides, immune modulators such as lymphokines, monokines, and cytokines, growth regulatory proteins, blood proteins, and antigens for viral, bacterial, and parasitic vaccines. Examples of other biological molecules that

-5-

can be used in this process include steroids, lipids, synthetic and naturally occurring drugs, and amino acids.

The process is shown schematically in Figures 1 and 2.

As depicted in Figure 1, the biologically active molecule is first dissolved in a solvent to form a solution 10 having a concentration ranging from approximately 0.1 to 25% (w/v). The solvent must be capable of being lyophilized. The solvent may be pure water or can be buffered to a particular pH or ionic strength. The solvent may also be organic. The solution may contain a single type of molecule, mixtures of two or more types of molecules, mixtures of biologically active molecules and stabilizers, or any combination thereof. In order to reduce the particle size of certain molecules to the greatest extent, the molecule should be suspended in a medium in which not only the solvent but also the buffer salts are volatile under conditions of lyophilization. Examples of volatile buffers removed by lyophilization include ammonium bicarbonate and other ammonium salts.

The solution 10 is then atomized and the resulting droplets sprayed into a low temperature liquified gas 12 using any one of several devices 14, such as ultrasonic nozzles, pressure nozzles, pneumatic nozzles and rotary nozzles. The liquified gas 12 can be liquid argon (-185.6°C), liquid nitrogen (-195.8°C), liquid oxygen (-182.9°C) or any other liquid gas that results in the immediate freezing of the atomized particles into frozen particles 15.

The droplets freeze instantly upon entering the cold liquified gas. The liquified gas 12 is removed by evaporation at a temperature at which the solvent remains frozen, leaving behind frozen droplets of solvent and biologically active molecules 16. The frozen solvent is removed from the droplets 16 by lyophilization to yield porous spheres 18. These spheres can vary in diameter depending on the technique used for their atomization, but generally range from approximately 10 to 90 micrometers.

This technique is particularly useful with proteins. When volatile buffer salts are used, the only solid remaining after lyophilization of the frozen spheres of solution containing the protein is the protein itself, with voids remaining in the space originally occupied by the volatile buffer. These voids minimize cohesion of protein-containing particles, permitting fragmentation of the protein particles into small pieces.

The porous spheres 18 can be used without further treatment if somewhat larger particle diameters are desirable. The porous spheres are useful in formulating polymeric drug delivery devices. When suspended in a polymer/solvent system in which the spheres 18 are not soluble, the result is a stable suspension 22 of the spheres 18. The choice of non-solvents that can be used for suspending the porous spheres depends on the nature of the molecules forming the spheres, as well as the polymer/solvent system. For proteins, exemplary non-solvents are acetone, ethyl acetate, methylene chloride, chloroform and tetrahydrofuran. The non-solvent for the porous spheres must be a solvent for the polymer. Exemplary polymer/solvent solutions in which proteins are not soluble include poly(lactic acid)/methylene chloride, poly(lactic-co-glycolic acid)/ethyl acetate and ethylene-vinyl acetate copolymer/methylene chloride. Such suspensions can be formed into controlled release systems in the shape of injectable microspheres or implantable matrices. These systems can be bioerodible or non-erodible.

The porous particles can also be incorporated in elixirs for medications, aerosol sprays for delivery to the lungs or nasal epithelium, suppositories, tablets and transdermal delivery systems.

As shown in Figure 2, the size of the porous spheres 18 is further decreased by suspending the spheres 18 in a non-solvent 20 such as ethanol, acetone, methylene chloride or ethyl acetate or any other solvent in which the molecules are not soluble. The suspension 22 is exposed to ultrasonic energy or other dispersive energy sources



-7-

such as homogenization, with continuous cooling, for various times to break up the porous spheres. In general, it is not desirable to subject the particles to energy in excess of that required to produce a particular diameter particle. The longer the suspension 22 is exposed to the ultrasonic energy, the smaller the size of the particles 24. This process results in the size reduction of the spheres 18 to yield particles 24 having an approximate size range of 0.1 to 10 micrometers diameter.

By selecting a non-solvent for the molecules in the particles which is also a solvent for a particular polymer, this step can be varied to produce uniform dispersions of small particles in polymer solutions, for the subsequent entrapment or encapsulation of the particles in a polymeric matrix.

The particles 24 are then removed from the sonicated suspension 26 by conventional methods known to those skilled in the art such as filtration, centrifugation or sieving. If the particles have been reduced in size in a polymer/solvent system, they can then be formed into devices such as microspheres, or processed into tablets, elixirs, aerosol sprays, suppositories or transdermal devices, using methods known to those skilled in the art.

The present invention will be further understood from the following non-limiting examples.

**Example 1:      Production of Horse Radish Peroxidase Particles**  
                          **having diameters of less than five micrometers as a**  
                          **function of ultrasonication time.**

A 250 mg sample of the enzyme horse radish peroxidase (HRP) (Sigma Chemical Co, St. Louis, MO.) was dissolved in 10 ml of a 0.05 M phosphate buffer solution having a pH of 7.2. The solution was atomized through an ultrasonic nozzle (SonoTek Corp., Model 8700-60MS) into a stirred container of liquid nitrogen. The liquid nitrogen containing the frozen atomized spheres was next placed in a -80°C freezer until the liquid nitrogen evaporated, about one to two

-8-

hours. The frozen protein spheres were then placed in a lyophilizer (Virtis Company Inc., Model 10-MR-TR) for at least 12 hours to produce porous particles. After lyophilization the diameter of the HRP spheres was determined by light microscopy to be within a range of 25-35 micrometers.

A 50 mg sample of the lyophilized microspheres was suspended in 5 ml of 100 percent ethanol solution and cooled in an ice water bath to 0°C. With continuous cooling, the HRP porous particles were then exposed to an ultrasonic probe (Virtis Company Inc., VirSonic 300) for different times. Samples were analyzed for particle size diameter on a Microtrac Model 7995 Small Particle Analyzer (Leeds and Northrup). Figure 3 shows the mean particle size plotted as a function of time of ultrasonication. Particle size decreased to under five micrometers after 100 seconds.

The activity of the HRP was determined after the lyophilization step and after the ultrasonication step. The method used to determine the enzyme activity is based upon the rate of oxidation of p-anisidine and is described in detail in The Worthington Enzyme Manual, Worthington, D.D., (ed.), Worthington Biochemical Corp., Freehold, NJ, p. 254 (1988). The HRP retained 90% or more of its original activity after each step of the particle size reduction process, indicating that the particle size reduction process has minimal effect on the activity of HRP.

Example 2:        **Production of Zinc Insulin Particles having diameters of less than four micrometers.**

The procedure in Example 1 was repeated using zinc insulin (American International Chemical, Inc., Natick, MA) dissolved in a 1.05 M citrate-phosphate buffer at a pH of 5.2. The mean particle diameter after five minutes sonication was  $3.2 \pm 2.5$  micrometers.

**Example 3:      Production of Catalase Particles having diameters of less than five micrometers.**

The procedure in Example 1 was repeated using catalase (Sigma Chemical Co.). The mean particle diameter after five minutes sonication was  $4.5 \pm 3.3$  micrometers.

**Example 4:      Production of Superoxide dismutase Particles having diameters of less than three micrometers.**

The procedure in Example 1 was repeated using superoxide dismutase (America International Chemicals, Inc.). The mean particle diameter after five minutes sonication was  $2.7 \pm 2.1$  micrometers.

The activity of the SOD was determined after the lyophilization step and after the ultrasonication step. The method used to determine the enzyme activity is based upon the ability of SOD to inhibit the reduction of nitro-blue tetrazolium by the superoxide anion. This assay is described in detail by Winterbourne, et al., in "The Estimation of Red Cell Superoxide Dismutase Activity," J. Lab. Clin. Med., 85, 337 (1975). After the lyophilization step, the SOD had 94% of its original activity. After the ultrasonication step, the SOD has 91% of its original activity. This indicates that the particle size reduction process has minimal effect on the activity of SOD.

**Example 5:      Production of Heparin Particles having diameters of less than seven micrometers.**

The procedure in Example 1 was repeated with all the conditions as described except that the macromolecule used was heparin (Diosynth, Inc.) dissolved in deionized water. The mean particle diameter after five minutes sonication was  $6.9 \pm 4.0$  micrometers.

**Example 6:      Production of Hemoglobin Particles having  
diameters of less than two micrometers.**

The procedure in Example 2 was repeated using bovine hemoglobin (Sigma Chemical Co.). The mean particle diameter after  
5 five minutes sonication was  $1.8 \pm 1.3$  micrometers.

**Example 7:      Production of Hemoglobin Particles having  
diameters of less than two micrometers using liquid  
argon.**

The procedure in Example 6 was repeated with all the  
10 conditions described except that the hemoglobin solution was sprayed  
into liquid argon before lyophilization. The mean particle diameter  
after 5 minutes sonication was  $3.6 \pm 2.8$  micrometers.

**Example 8:      Production of HRP Particles having diameters of  
less than five micrometers as a function of pH.**

15 The procedure in Example 1 was repeated with all the  
conditions as described except that three different buffers with  
different pH's were used to dissolve the HRP: a citrate/phosphate  
buffer, pH 5.2; a phosphate buffer, pH 7.2 and a tris buffer, pH 9.1.  
The lyophilized particles were sonicated for 5 min and their particle  
20 size determined, as shown in Table 1.

**TABLE 1:      Particle Size of Sonicated HRP as a function  
of Buffer pH.**

<u>Buffer pH</u>	<u>Particle Size (<math>\mu</math>M)</u>
5.2	$2.9 \pm 2.1$
7.2	$3.5 \pm 2.8$
9.1	$6.2 \pm 3.7$

**Example 9:      Production of Dextran Particles having diameters of less than five micrometers as a function of initial dextran concentration.**

The procedure in Example 1 was repeated using dextran  
5 (Sigma Chemical Co., mw 40,200) at concentrations of 20, 10, 5, 1, 2.5 and 0.5 percent. The particle size of these samples was determined after being suspended in 100 percent ethanol and ultrasonicated for five minutes.

Figure 4 shows the mean particle size of the dextran as a  
10 function of the dextran solution concentration used to make the macromolecule spheres. The results demonstrate that the smallest particles are produced using 0.5 to 5% dextran solutions.

**Example 10:      Production of Superoxide dismutase-dextran  
15                      Particles having diameters of less than seven micrometers.**

A 125 mg sample of SOD and a 125 mg sample of dextran  
were dissolved in a 0.05 M citrate-phosphate buffer solution at a pH  
of 5.2. The aqueous solution was atomized into liquid nitrogen and  
processed as described in Example 1. The mean particle diameter  
20 after five minutes sonication was  $6.9 \pm 6.5$  micrometers.

**Example 11:      Production of Hemoglobin Particles having  
                         diameters of less than four micrometers using  
                         ammonium bicarbonate as a buffer component.**

125 mg bovine hemoglobin dissolved in 5 ml 0.05 M  
25 ammonium bicarbonate was formed into particles by spraying and lyophilization, according to the procedure of Example 1. Scanning electron micrographs (SEM) of the particles showed spheres having an exterior film and a spongy interior, with sizes ranging from 15 to 70 micrometers in diameter. A control solution containing only  
30 ammonium bicarbonate was also sprayed and lyophilized as described in Example 1. The absence of any solid residue after lyophilization demonstrated the volatility of the buffer salt under these conditions.

-12-

The hemoglobin particles were suspended in ethyl acetate and fragmented by subjecting them to ultrasonic irradiation with cooling by an ice bath. When the resulting particles were subjected to particle size analysis using a Leeds & Northrup Microtrac small particle analyzer, the mean particle diameter was  $3.7 \pm 2.8$  micrometers. SEM of sonicated particles showed flat irregular plates with lengths on the order of 1.0 micrometer, with a thickness of 0.1 micrometer.

**Example 12:** Production of Hemoglobin Particles having diameters of less than seven micrometers using homogenization.

A portion of the spherical particles of hemoglobin prepared in Example 11 were fragmented by suspending them in ethyl acetate and homogenizing them using a homogenizer (Brinkmann Instruments Co., Switzerland), instead of by ultrasonic irradiation. Particle size analysis of the resulting fragmented particles gave a size distribution for the effective diameters after 80 sec of homogenization of  $7.2 \pm 3.7$  micrometers. After 300 sec of homogenization, the particle diameter size distribution was  $6.6 \pm 3.7$  micrometers.

The homogenized hemoglobin particles were stored in ethyl acetate for seven days, after which the solvent was decanted and the hemoglobin dried under vacuum at room temperature. The resulting solid was dissolved in 0.2 M sodium phosphate pH 7.7, and its heme absorption compared with that of freshly dissolved bovine hemoglobin, as well as with hemoglobin denatured in 6 M guanidinium chloride, using a Hewlett Packard diode array spectrophotometer. In order to accentuate spectral features, the second derivative of absorption with respect to wavelength was obtained for each sample. The results are shown in Figure 5. The spectra demonstrate that the samples of fresh hemoglobin and hemoglobin processed by the method described herein are identical and differ drastically from the curve for denatured

-13-

hemoglobin, indicating that the particle reduction process does not cause significant alterations in the protein molecule.

**Example 13: Production of Horse Radish Peroxidase Particles having diameters of less than three micrometers using ammonium bicarbonate as a buffer component.**

Horse radish peroxidase frozen particles were prepared and subjected to ultrasonic fragmentation as described for hemoglobin in Example 11. The size distribution for the effective diameters of the resulting particles was  $2.8 \pm 2.2$  micrometers. The HRP particles retained 90% of their activity during this process, as assayed by the method described in Example 1.

**Example 14: Production of Bovine Serum Albumin Particles having diameters of less than two micrometers using ammonium bicarbonate as a buffer component.**

Bovine serum albumin (BSA) was suspended in 0, 4, 20 and 100 mg of ammonium bicarbonate/ml water to a concentration of 25 mg BSA/ml, and protein particles prepared as described for hemoglobin in Example 11. Under light microscopy, the BSA particles prepared from BSA solutions in 100 mg ammonium bicarbonate/ml solution contained extremely filamentous, airy strands of protein. The particles prepared from BSA in the other ammonium bicarbonate solutions also appeared filamentous but were more dense.

The sample prepared from 100 mg ammonium bicarbonate/ ml was suspended in ethyl acetate and fragmented by ultrasonic irradiation. The resulting preparation gave a size distribution having more than 60% of the particles less than 1.7 micrometers in diameter. Under light microscopy virtually all the particles were less than 1 micrometer in size.

**Example 15:      Production of Glycine Particles having a diameter of less than 3.5 micrometers.**

A 2.5% solution of Glycine (EM Science) was prepared in deionized water. This was ultrasonicated to form frozen particles which were lyophilized according to the procedure of Example 1. Light microscopy revealed porous particles having a mean diameter of  $24.4 \pm 14.6$  micrometers. These porous particles were fragmented by ultrasonication for 4 min, producing particles having a mean diameter of  $3.2 \pm 1.9$  micrometers. This example demonstrates the utility of this particles for reducing the particle size of low molecular weight compounds such as glycine (75.07 daltons).

**Example 16:      Production of Testosterone Particles from 1,4 Dioxane having a diameter of less than five micrometers.**

The procedure in example 1 was repeated using a 2.5% solution of testosterone (Sigma Chemical Co.) in 1,4 dioxane. The resulting particles had a mean diameter of  $5.4 \pm 2.9$  micrometers, demonstrating the effectiveness of the procedure to prepare small particles of steroids in organic solvents.

**Example 17:      Production of Stable suspension of porous BSA Particles.**

A 1.994 gm sample of bovine serum albumin (BSA) (Sigma Chemical Co.) was dissolved in 80 ml of deionized water, atomized through an ultrasonic nozzle into liquid nitrogen and lyophilized. The particle diameter of the porous spheres ranged from 20-30 micrometers.

Samples of these BSA particles were suspended in a 10 percent (w/v) solution of ethylene-vinyl acetate (USI Chemicals Co.) in methylene chloride, resulting in mixtures containing 5, 10 and 20 percent by weight of protein. All of these solutions contained stable suspensions of the BSA and the BSA did not settle to the bottom of



-15-

the solution with time. It is believed that the solvent diffuses into the porous particles, equalizing the density of the particles with that of the polymer-solvent solution.

- Modifications and variations of the method for making
- 5 biologically active, small diameter particles will be obvious to those skilled in the art from the foregoing detailed description of the invention. Such modifications and variations are intended to come within the scope of the appended claims.

-16-

We claim.

1. A process for making porous particles of biologically active molecules having a diameter of approximately 10 to 90 micrometers comprising:

providing a solution of biologically active molecules selected from the group consisting of carbohydrates, polysaccharides, nucleotides, inorganic compounds, organic molecules, peptides, proteins, nucleoproteins, glycoproteins, and lipoproteins, in a solvent that can be removed by lyophilization;

atomizing the solution into a liquified gas in a vessel to produce frozen droplets containing biologically active molecules in combination with the solvent;

removing the liquified gas from the vessel containing the frozen particles; and

removing the solvent from the particles by lyophilization to produce porous particles.

2. The process of claim 1 wherein the liquified gas is selected from the group consisting of nitrogen, argon, and oxygen.

3. The process of claim 1 further comprising selecting an aqueous solvent and adjusting the pH, ionic strength, and concentrations of dissolved biologically active molecules in the solution.

4. The process of claim 3 wherein volatile salts which can be removed using lyophilization are used to buffer the solution.

5. The process of claim 1 wherein the solution is atomized through an ultrasonic nozzle.

-17-

6. The process of claim 1 further comprising suspending the 10 to 90 micrometer diameter porous particles in a polymer-solvent solution selected from the group consisting of poly(lactic acid)/methylene chloride, poly(lactic-co-glycolic acid)/ethyl acetate and ethylene-vinyl acetate copolymer/methylene chloride.

7. The process of claim 1 further comprising making particles of biologically active molecules having diameters of between approximately 0.1 and 10 micrometers by suspending the 10 to 90 micrometer porous particles in a non-solvent for the biologically active molecules.

8. The process of claim 7 further comprising fragmenting the suspension of particles until particles having diameters of approximately 0.1 to 10 micrometers are produced.

9. The process of claim 8 further comprising removing the 0.1 to 10 micrometer particles from the non-solvent.

10. The process of claim 8 further comprising incorporating the 0.1 to 10 micrometer particles in a polymeric matrix.

11. Porous particles of biologically active molecules having a diameter of between approximately 10 and 50 micrometers, containing molecules having greater than 70% of the activity of the molecules in solution prior to forming the particles, wherein the particles are produced by

providing a solution of biologically active molecules selected from the group consisting of carbohydrates, polysaccharides, nucleotides, inorganic compounds, organic molecules, peptides, proteins, nucleoproteins, glycoproteins, and lipoproteins, in a solvent that can be removed by lyophilization;

-18-

atomizing the solution into a liquified gas in a vessel to produce frozen particles containing biologically active molecules in combination with the solvent;

removing the gas from the vessel containing the frozen particles; and

removing the solvent from the particles by lyophilization to produce porous particles of biologically active molecules having a diameter of between approximately 10 and 50 micrometers.

12. The porous particles of claim 11 further comprising a polymeric matrix.

13. The porous particles of claim 12 wherein the polymeric matrix is formed of poly(lactic acid), poly(lactic-co-glycolic acid), ethylene-vinyl acetate, copolymers and blends thereof.

14. Particles of biologically active molecules having a diameter of between approximately 0.1 and 10 micrometers, containing molecules having greater than 70% of the activity of the molecules in solution prior to forming the particles, wherein the particles are produced by

providing a solution of biologically active molecules selected from the group consisting of carbohydrates, polysaccharides, nucleotides, inorganic compounds, organic molecules, polypeptides, nucleoproteins, glycoproteins, and lipoproteins, in a solvent that can be removed by lyophilization;

atomizing the solution into a liquified gas in a vessel to produce frozen particles containing biologically active molecules in combination with the solvent;

removing the gas from the vessel containing the frozen particles;

removing the solvent from the particles by lyophilization to produce porous particles;


suspending the porous particles in a non-solvent for the biologically active molecules; and

fragmenting the porous particles into particles having diameters of approximately 0.1 to 10 micrometers.

15. The porous particles of claim 11 further comprising a polymeric matrix.


16. The porous particles of claim 15 wherein the polymeric matrix is formed of poly(lactic acid), poly(lactic-co-glycolic acid), ethylene-vinyl acetate, copolymers and blends thereof.

1/4

**fig. 1**

2/4

fig. 2






**fig. 3****fig. 4**



fig. 5



# INTERNATIONAL SEARCH REPORT

International Application No PCT/US 90/02421

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) <sup>6</sup> According to International Patent Classification (IPC) or to both National Classification and IPC IPC <sup>5</sup> :     A 61 K 9/16, B 01 J 10/00		
<b>II. FIELDS SEARCHED</b> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Minimum Documentation Searched <sup>7</sup></div> <div style="display: flex; justify-content: space-between;"> <span>Classification System  </span> <span>Classification Symbols</span> </div> <div style="padding: 10px 0;">             IPC<sup>5</sup>     :     A 61 K                       :     :                       :     :           </div> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched <sup>8</sup></div>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup></b>		
Category <sup>9</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
Y	Review of Scientific Instruments, vol. 57, no. 8, part 1, August 1986, American Institute of Physics, (New York, NY, US), D.E. Himberger et al.: "Low-tempera- ture acoustic system for inducing nonthermal ultrasonic damage on biological targets", pages 1681-1683, se page 1681	1
A	--	2
Y	US, A, 2752097 (J. LECHER) 26 June 1956 see claim 1.	1
	--	
./.		
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p><sup>10</sup> Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search  <div style="text-align: center; font-weight: bold;">23rd August 1990</div>	Date of Mailing of this International Search Report  <div style="text-align: center; font-weight: bold;">19. 09. 90</div>	
International Searching Authority  <div style="text-align: center; font-weight: bold;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer  <div style="text-align: center;">             R.J. Eernisse  </div>	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, " with indication, where appropriate, of the relevant passages	Relevant to Claim No.
Y	GB, A, 2077693 (SANDOZ) - 23 December 1981 see claim 1; example 7	1
A	--	12,13
Y	Pharmaceutisch Weekblad, vol. 106, 1971, (Amsterdam, NL), C.F. Lerk et al.: "De bereiding van uniforme granules door vibratie- sproeistollen", pages 149-157, see pages 149,150	1
	-----	

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.**

US 9002421  
SA 37142

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 17/09/90. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A- 2752097		None	
GB-A- 2077693	23-12-81	US-A- 4384975	24-05-83
		CH-A- 648217	15-03-85
		DE-A- 3121983	04-02-82
		FR-A, B 2484281	18-12-81
		JP-A- 57027128	13-02-82
		US-A- 4933105	12-06-90